Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,283.40 +5.89 (+0.11%) Dow
38,571.03 -115.29 (-0.30%) Nasdaq
16,828.67 +93.65 (+0.56%) Bitcoin USD
69,054.91 +1,279.28 (+1.89%) CMC Crypto 200
1,444.76 -23.18 (-1.58%)
AZN Jun 2024 67.000 put
| Previous close | 0.0800 |
| Open | 0.0800 |
| Bid | 0.0000 |
| Ask | 2.1400 |
| Strike | 67.00 |
| Expiry date | 2024-06-14 |
| Day's range | 0.0800 - 0.0800 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ZacksAstrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Astrazeneca (AZN) closed at $78.99, marking a +1.24% move from the previous day.
Business WireTAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
WILMINGTON, Del., June 02, 2024--Positive results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose tumors have exon 19 deletions or exon 21 (L858R) mutations, after chemoradiotherapy (CRT) compared to placebo after CRT.
Business WireIMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
WILMINGTON, Del., June 02, 2024--Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to placebo for patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following standard-of-care concurrent chemoradiotherapy (cCRT).
